Twiggy’s biotech gets US tick for cardiac treatment

Admedus , the early stage biotechnology company that counts mining magnate Andrew ‘Twiggy’ Forrest as a cornerstone investor, has passed an important milestone with its regenerative tissue treatment for heart defects receiving approval to be sold in the United States.

The company has previously received approval in Europe for its CardioCel product and on Monday announced that it had received clearance from the US regulator, the Food and Drug Administration.